中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives

文献类型：期刊论文

作者Ding, Bingwen3,4,5; Zhu, Zhu2,4,5; Guo, Cong3,4,5; Li, Jiaxin3,4,5; Gan, Yong1,3,4,5; Yu, Miaorong3,4,5
刊名ACTA PHARMACEUTICA SINICA B
出版日期2024-05-01
卷号14期号:5页码:2006-2025
关键词Oral peptides Diabetes Delivery platforms Insulin Glucagon-like peptide-1 Biodistribution Biological barriers Targeted delivery
ISSN号2211-3835
DOI10.1016/j.apsb.2024.02.019
通讯作者Gan, Yong(ygan@simm.ac.cn) ; Yu, Miaorong(mryu@simm.ac.cn)
英文摘要Diabetes, characterized by hyperglycemia, is a major cause of death and disability worldwide. Peptides, such as insulin and glucagon-like peptide-1 (GLP-1) analogs, have shown promise as treatments for diabetes due to their ability to mimic or enhance insulin's actions in the body. Compared to subcutaneous injection, oral administration of anti-diabetic peptides is a preferred approach. However, biological barriers significantly reduce the efficacy of oral peptide therapeutics. Recent advancements in drug delivery systems and formulation techniques have greatly improved the oral delivery of peptide therapeutics and their efficacy in treating diabetes. This review will highlight (1) the benefits of oral anti- diabetic peptide therapeutics; (2) the biological barriers for oral peptide delivery, including pH and enzyme degradation, intestinal mucosa barrier, and biodistribution barrier; (3) the delivery platforms to overcome these biological barriers. Additionally, the review will discuss the prospects in this field. The information provided in this review will serve as a valuable guide for future developments in oral anti-diabetic peptide therapeutics.
WOS关键词MUCUS-PERMEATING NANOPARTICLES ; DRUG-DELIVERY-SYSTEM ; INSULIN DELIVERY ; POLYMERIC NANOPARTICLES ; INTESTINAL PERMEABILITY ; ABSORPTION ENHANCEMENT ; ENHANCING MECHANISM ; PROTEASE INHIBITORS ; MULTIPLE BARRIERS ; RECEPTOR AGONISTS
资助项目National Science Fund of Distinguished Young Scholars, China[82025032] ; National Natural Science Foundation of China, China[82073773] ; Key Research Program of Chinese Academy of Sciences, China[ZDBS-ZRKJZ-TLC005] ; Young Elite Scientists Sponsorship Program by CAST, China[2022QNRC001]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001289807000001
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
源URL[http://119.78.100.183/handle/2S10ELR8/312682]  
专题新药研究国家重点实验室
通讯作者Gan, Yong; Yu, Miaorong
作者单位1.Natl Inst Food & Drug Control, NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipie, Beijing 100050, Peoples R China
2.Henan Univ, Sch Pharm, Kaifeng 475004, Peoples R China
3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Ding, Bingwen,Zhu, Zhu,Guo, Cong,et al. Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives[J]. ACTA PHARMACEUTICA SINICA B,2024,14(5):2006-2025.
APA Ding, Bingwen,Zhu, Zhu,Guo, Cong,Li, Jiaxin,Gan, Yong,&Yu, Miaorong.(2024).Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives.ACTA PHARMACEUTICA SINICA B,14(5),2006-2025.
MLA Ding, Bingwen,et al."Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives".ACTA PHARMACEUTICA SINICA B 14.5(2024):2006-2025.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。